Is Predictive Oncology, Inc. overvalued or undervalued?

As of 14 August 2018, the valuation grade for Predictive Oncology, Inc. moved from does not qualify to risky. The company appears to be overvalued given its negative financial metrics, including a P/E ratio that is not applicable due to losses, a price-to-book value of -8.38, and an EV to EBITDA ratio of -0.61. These indicators suggest significant financial distress and a lack of profitability.
In comparison to peers, Predictive Oncology's EV to EBITDA ratio of -0.5937 is notably worse than Nutriband, Inc., which has a ratio of -14.0891, and STRATA Skin Sciences, Inc. with a ratio of 17.2262, highlighting the company's relative weakness in generating earnings before interest, taxes, depreciation, and amortization. The company's stock has underperformed against the S&P 500 over various time frames, particularly over the last three and five years, where it has declined by 89.73% and 97.82%, respectively, while the S&P 500 has seen significant gains. Overall, these factors indicate that Predictive Oncology, Inc. is overvalued in its current state.